journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Clinical Dermatology

journal
https://www.readbyqxmd.com/read/29453712/author-correction-to-psoriasis-in-skin-of-color-insights-into-the-epidemiology-clinical-presentation-genetics-quality-of-life-impact-and-treatment-of-psoriasis-in-non-white-racial-ethnic-groups
#1
Bridget P Kaufman, Andrew F Alexis
In the original publication, section 5, paragraph 1 was incorrectly published.
February 16, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29417399/melanoma-brain-metastases-local-therapies-targeted-therapies-immune-checkpoint-inhibitors-and-their-combinations-chances-and-challenges
#2
REVIEW
Marvin Kuske, Ricarda Rauschenberg, Marlene Garzarolli, Michelle Meredyth-Stewart, Stefan Beissert, Esther G C Troost, Oliva Isabella Claudia Glitza, Friedegund Meier
Recent phase II trials have shown that BRAF/MEK inhibitors and immune checkpoint inhibitors are active in patients with melanoma brain metastases (MBM), reporting intracranial disease control rates of 50-75%. Furthermore, retrospective analyses suggest that combining stereotactic radiosurgery with immune checkpoint inhibitors or BRAF/MEK inhibitors prolongs overall survival. These data stress the need for inter- and multidisciplinary cooperation that takes into account the individual prognostic factors in order to establish the best treatment for each patient...
February 7, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29396702/a-phase-ii-randomized-double-blind-clinical-study-evaluating-the-safety-tolerability-and-efficacy-of-a-topical-minocycline-foam-fmx103-for-the-treatment-of-facial-papulopustular-rosacea
#3
Ulrich Mrowietz, Tal Hetzroni Kedem, Rita Keynan, Meir Eini, Dov Tamarkin, Dror Rom, Mitchell Shirvan
OBJECTIVE: Our objective was to demonstrate the safety, tolerability, and efficacy of a minocycline foam, FMX103, in the treatment of moderate-to-severe facial papulopustular rosacea. METHODS: This was a phase II, randomized, double-blind, multicenter study. Healthy subjects aged ≥ 18 years with moderate-to-severe rosacea that had been diagnosed ≥ 6 months previously and with ≥ 12 inflammatory facial lesions were randomized (1:1:1) to receive once-daily 1...
February 2, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29392620/treatment-of-autoimmune-bullous-disorders-in-pregnancy
#4
REVIEW
Carolyn J Kushner, Josef Symon S Concha, Victoria P Werth
Autoimmune bullous diseases (AIBD), including pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita, mucous membrane pemphigoid, and pemphigoid gestationis, pose significant therapeutic challenges, especially in pregnant and post-partum breastfeeding patients or those planning to conceive. Data on the safety and efficacy of therapeutic interventions during the perinatal period are lacking because randomized controlled trials are typically not performed in this setting. However, many of the treatments for AIBD are also used in other diseases, so data can be extrapolated from studies or case reports in these other patient populations...
February 2, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29380251/safety-of-adalimumab-dosed-every-week-and-every-other-week-focus-on-patients-with-hidradenitis-suppurativa-or-psoriasis
#5
Caitriona Ryan, Jeffrey M Sobell, Craig L Leonardi, Charles W Lynde, Mahinda Karunaratne, Wendell C Valdecantos, Barbara A Hendrickson
BACKGROUND: Adalimumab is approved for the treatment of hidradenitis suppurativa (HS), plaque psoriasis, and other inflammatory conditions. OBJECTIVE: Our objective was to examine the safety of adalimumab administered every other week (EOW) and every week (EW) in patients with HS and psoriasis and to investigate informative data from non-dermatologic indications. METHODS: The safety of adalimumab 40-mg EOW versus EW dosing was examined during placebo-controlled and open-label study periods in patients with HS (three studies), psoriasis (two studies), Crohn's disease (six studies), ulcerative colitis (three studies), and rheumatoid arthritis (one study)...
January 27, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29368043/comparison-of-urticaria-activity-score-over-7%C3%A2-days-uas7-values-obtained-from-once-daily-and-twice-daily-versions-results-from-the-assure-csu-study
#6
Kelly Hollis, Christina Proctor, Doreen McBride, Maria-Magdalena Balp, Lori McLeod, Shannon Hunter, Haijun Tian, Sam Khalil, Marcus Maurer
BACKGROUND: The Urticaria Activity Score summed over 7 days (UAS7) assesses the itch severity and hive count in chronic spontaneous urticaria (CSU) using once- or twice-daily diary-based documentation. OBJECTIVE: The aim of this study was to evaluate the comparability of twice-daily versus once-daily versions of the UAS and the resulting UAS7 values. METHODS: Data came from the ASSURE-CSU study. The twice-daily and once-daily UAS7 was calculated from morning and evening ratings, as well as from exact 24-h evening ratings of hive count and itch severity, respectively...
January 24, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29352423/understanding-and-addressing-hair-disorders-in-transgender-individuals
#7
REVIEW
Yi Gao, Toby Maurer, Paradi Mirmirani
In the United States, an increasing number of individuals are identifying as transgender. Males at birth who identify as females are called male-to-female (MTF) transgender individuals or trans women, and females at birth who identify as males are called female-to-male (FTM) transgender individuals or trans men. The transgender patient population possess unique health concerns disparate from those of the general populace. Exogenous hormone therapy for transgender patients leads to changes in the distribution and pattern of hair growth...
January 19, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29305764/the-role-and-diagnosis-of-allergic-contact-dermatitis-in-patients-with-atopic-dermatitis
#8
Joshua L Owen, Paras P Vakharia, Jonathan I Silverberg
Patients with atopic dermatitis (AD) have increased penetration of allergens, immune dysregulation (including shared cytokine pathways), and frequent use of emollients and topical medications, all of which may predispose toward developing allergic contact dermatitis (ACD). Recent systematic reviews have suggested that ACD is a significant clinical problem in both children and adults with AD. While this remains controversial, ACD remains an important comorbidity and potential exacerbant of AD in clinical practice...
January 5, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29302927/a-review-on-pityriasis-rubra-pilaris
#9
REVIEW
Dingyuan Wang, Vanessa Cui-Lian Chong, Wei-Sheng Chong, Hazel H Oon
Pityriasis rubra pilaris (PRP) is an idiopathic, papulosquamous inflammatory dermatosis. It is characterized by hyperkeratotic follicular papules coalescing into orange-red scaly plaques, islands of sparing, and palmoplantar keratoderma. PRP can be subdivided into six clinical subtypes according to Griffiths' classification, based on age of onset, disease extent, prognosis, and other associated features. The sixth subtype of PRP occurs in individuals affected by HIV infection, and retroviral screening in all de novo cases of PRP is advised...
January 4, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29285724/management-of-itch-in-atopic-dermatitis
#10
REVIEW
Janelle Pavlis, Gil Yosipovitch
Atopic dermatitis (AD) is the most common itchy dermatosis that affects millions of children and adults worldwide. Chronic itch in this condition has significant impact on measures of quality of life, such as sleep. Treating itch in AD has been challenging for decades, but new drugs have emerged in the last year with significant anti-pruritic effect. The optimal treatment regimen for atopic itch addresses barrier dysfunction, inflammation, neural hypersensitivity, and the itch-scratch cycle. Topical moisturizers remain the foundation of treatment and should be used by all patients with AD-associated pruritus...
December 28, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29260411/malignancy-risk-and-recurrence-with-psoriasis-and-its-treatments-a-concise-update
#11
REVIEW
Shamir Geller, Haoming Xu, Mark Lebwohl, Beatrice Nardone, Mario E Lacouture, Meenal Kheterpal
Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Studies on methotrexate and cyclosporine, as well as older biological agents such as tumor necrosis factor inhibitors, have found no increased risk of non-cutaneous solid tumors; however, positive associations between cutaneous squamous cell carcinomas and certain therapies have been found...
December 19, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29256113/dermatologic-reactions-to-immune-checkpoint-inhibitors-skin-toxicities-and-immunotherapy
#12
REVIEW
Vincent Sibaud
The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1)] represents a major breakthrough in cancer therapy. Although they present a favorable risk/benefit ratio, immune checkpoint blockade therapies have a very specific safety profile. Due to their unique mechanism of action, they entail a new spectrum of adverse events that are mostly immune related [immune-related adverse events (irAEs)], notably mediated by the triggering of cytotoxic CD4+/CD8+ T cell activation...
December 18, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29230666/granuloma-annulare-a-focused-review-of-therapeutic-options
#13
REVIEW
Jenny Wang, Amor Khachemoune
Granuloma annulare (GA) is a benign inflammatory disease associated with many conditions such as malignancy, trauma, thyroid disease, diabetes mellitus, and HIV infection. Common clinical subtypes include localized GA, generalized GA, subcutaneous GA, perforating GA, and patch GA. There exists an abundance of literature on GA, yet we know relatively little about its exact etiology and even less about its treatment. The paucity of conclusive data on effective treatment options is largely because the majority of published studies are limited to small case reports, case series, and retrospective studies...
December 11, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29222629/postinflammatory-hyperpigmentation-epidemiology-clinical-presentation-pathogenesis-and-treatment
#14
REVIEW
Bridget P Kaufman, Taulun Aman, Andrew F Alexis
Postinflammatory hyperpigmentation (PIH) is a reactive hypermelanosis that develops following cutaneous inflammation. Common causes of PIH include intrinsic skin conditions (e.g., acne and eczema) as well as external insults to the skin, such as burn injuries and dermatologic procedures. PIH more commonly occurs in individuals with darker skin, for whom it is often a source of significant psychological distress. Several therapeutic modalities are available for the treatment of PIH, including topical agents, chemical peels, and energy-based devices...
December 8, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29209945/psoriasis-in-skin-of-color-insights-into-the-epidemiology-clinical-presentation-genetics-quality-of-life-impact-and-treatment-of-psoriasis-in-non-white-racial-ethnic-groups
#15
REVIEW
Bridget P Kaufman, Andrew F Alexis
Psoriasis is a chronic inflammatory skin condition affecting diverse racial/ethnic groups throughout the world. Large population-based studies suggest that psoriasis occurs most often in individuals of European ancestry, followed by black and Hispanic individuals, although the true prevalence of psoriasis in non-white individuals is likely underestimated. Despite similarities in psoriasis between ethnic groups, there are notable differences in the presentation, quality-of-life impact, and treatment of psoriasis with important implications for the management of non-white individuals...
December 5, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29340955/adult-atopic-dermatitis-is-associated-with-increased-aortic-stiffness
#16
LETTER
Győző Szolnoky, Anita Altmayer, József Varga, Henriette Gavallér, Lajos Kemény, Tamás Forster, Attila Nemes
No abstract text is available yet for this article.
February 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28707186/natural-oils-for-skin-barrier-repair-ancient-compounds-now-backed-by-modern-science
#17
REVIEW
Alexandra R Vaughn, Ashley K Clark, Raja K Sivamani, Vivian Y Shi
Natural plant oils are commonly used as topical therapy worldwide. They are usually easily accessible and are relatively inexpensive options for skin care. Many natural oils possess specific compounds with antimicrobial, antioxidant, anti-inflammatory, and anti-itch properties, making them attractive alternative and complementary treatments for xerotic and inflammatory dermatoses associated with skin-barrier disruption. Unique characteristics of various oils are important when considering their use for topical skin care...
February 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29076116/crisaborole-ointment-2-a-review-in-mild-to-moderate-atopic-dermatitis
#18
REVIEW
Sheridan M Hoy
Crisaborole ointment 2% (Eucrisa™) is a novel, anti-inflammatory inhibitor of phosphodiesterase 4 (PDE4) that is available in the USA for the topical treatment of mild to moderate atopic dermatitis in patients aged ≥ 2 years. In two short-term (28 days), identically designed, multicentre, phase III studies in this patient population, topical therapy with crisaborole ointment 2% reduced disease severity and pruritus severity compared with vehicle, with the effect established early and sustained over the course of treatment...
December 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28733947/improvement-of-rosacea-during-acyclovir-treatment-a-case-report
#19
LETTER
Zohreh Sadat Badieyan, Sayed Shahabuddin Hoseini
No abstract text is available yet for this article.
December 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28681230/probiotics-prebiotics-and-synbiotics-for-the-treatment-and-prevention-of-adult-dermatological-diseases
#20
REVIEW
Manisha Notay, Negar Foolad, Alexandra R Vaughn, Raja K Sivamani
BACKGROUND: Probiotic, prebiotic, and synbiotic supplementation is becoming more prevalent nowadays. Clinical studies have demonstrated some of the medical benefits of probiotics, prebiotics, and synbiotics within dermatology but an evidence-based review of their effects in adults is needed. OBJECTIVE: The aim of this study was to identify evidence for the use of supplementation with probiotics, prebiotics, or synbiotics for the prevention and treatment of dermatological diseases in adults...
December 2017: American Journal of Clinical Dermatology
journal
journal
34795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"